Compare Fabrinet (FN) vs Moderna, Inc. (MRNA) Price & Performance

Fabrinet (FN) trades at $486.28, down 2.35% today but maintains strong analyst support with 75% buy ratings and a $769.50 consensus price target. The stock shows bullish technical signals with support at $477 and resistance at $498, while recent earnings beats highlight robust AI data-center demand driving 45% revenue growth in Q4 2026. Valuation metrics include a P/E of 37.34 and ROE of 21.33%, reflecting premium pricing for high growth.

Outlook remains positive with multi-year AI infrastructure expansion, though risks include customer concentration and margin pressure from capital expenditures. The stock offers significant upside to analyst targets if execution continues, but volatility may persist near current levels.

Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.

While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.